Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Inclusion Criteria:

• Patients with Parkinson's Disease on a stable regimen of antiparkinson'smedications, including a levodopa preparation administered not less than 3 timesdaily.

• Meet protocol-specified criteria for moderate to severe dyskinesia symptoms based onUDysRS and Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assessments.

• Meet protocol specified criteria for ON time with troublesome dyskinesia based on astandard PD home diary.

Exclusion Criteria:

• Prior surgical treatment for Parkinson's Disease (e.g., deep brain stimulation).

• Other neurological disease (including psychiatric disease and/or cognitiveimpairment) that, in the opinion of the investigator, would affect the patient'sability to complete study assessments.

• Other significant medical condition that may affect the safety of the patient orpreclude adequate participation in the study.

• Pregnant or breast-feeding. Female patients who are of child-bearing potential mustbe using adequate contraceptive methods (e.g. oral contraceptive, double-barriermethod, intra-uterine device, intra-muscular hormonal contraceptive), and have anegative pregnancy test at Screening.

Other protocol-defined inclusion and exclusion criteria may apply